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1. Introduction 
Renal biopsy is an essential tool for the diagnosis of several renal diseases. The first renal 
biopsies were performed in 1923 as open surgical procedures (Gwyn, 1923). The 
percutaneous approach has been part of the clinical practice since 1951 (Iversen & Brun, 
1951). A few years later, a description of the procedure with the patient placed in a prone 
position was published (Kark & Muehrcke, 1954). The new technique had a success rate of 
more than 90% and was not associated with major complications. Percutaneous ultrasound-
guided renal biopsy is now considered as the standard method. It is a routine procedure 
that can be done with minimal discomfort to the patient. Here we review major topics 
related to this frequent and useful procedure in the field of nephrology. 
2. Indications 
Although indications for renal biopsy can sometimes be a matter of debate among 
nephrologists, common indications include: isolated hematuria, mild to moderate 
proteinuria, nephrotic syndrome, glomerulonephritis, acute renal failure, renal 
manifestations of systemic diseases and chronic renal failure (Table 1). There is also an 
important role for percutaneous kidney biopsy in kidney transplantation. Percutaneous 
kidney biopsy is not only reserved for the diagnosis of renal parenchymal diseases, but it 
may also have a role in the diagnosis of renal tumor as described below in this chapter. 
Impacts of diagnosis made by kidney biopsy have to take into account considerations 
beyond therapeutic implications. A kidney disease diagnosis within the patient’s records 
could have psychological and financial consequences (e.g. insurances), and can modify 
family planning decisions (e.g. hereditary renal diseases) (Korbet, 2002). Performing a 
percutaneous kidney biopsy therefore implies a good communication between the attending 
physician and his patient. 
3. Contraindications 
In 1988, the Health and Public Policy Committee of American College of Physicians (ACP) 
elaborated a list of contraindications to kidney biopsy (ACP, 1988). As described below,  
the relevance of this policy may be actually questioned upon recent technological 
developments resulting in a virtual absence of catastrophic complications in recent series 
(Waldo et al., 2009). 
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3.1 Absolute contraindications 
Several contraindications to renal biopsy have been described (Madaio, 1990). Absolute 
contraindications are generally recognized as uncontrolled bleeding diathesis, anatomic 
abnormalities, uncooperative behaviour and pregnancy (Table 1). Chronic renal disease 
associated with two small kidneys with cortical atrophy remains a contraindication to renal 
biopsy, since the bleeding risk is high, but can be considered relative if performed by a well-
experienced operator. Absence of an appropriate pathologic support makes no sense to 
perform a biopsy and should therefore be considered as a contraindication (Korbet, 2002). 
Single functioning kidney is not considered as an absolute contraindication anymore 
because of technical and real-time imaging improvements over the last decades. As stated in 
a report of nine cases of normal size solitary kidney biopsy, it can be performed with good 
outcomes in terms of bleeding and renal function (Mendelssohn & Cole, 1995). In this series, 
the only complication reported was post-procedure gross hematuria in one patient. 
Histopathological diagnosis was made in eight of nine cases. 
One can argue that an uncooperative patient is no longer an absolute contraindication in 
particular circumstances. Intensive care unit patients on mechanical ventilation appear to 
tolerate well bedside biopsy with appropriate administration of sedative agents (Conlon et 
al., 1995). The procedure is performed off ventilator with ventilation controlled with an 
ambu bag, permitting a perfect synchronization between respiratory movements and needle 
insertion, thereby minimizing risks of complications. 
3.2 Relative contraindications 
Relative contraindications consist in conditions that may be reversed, sometimes relatively 
easily; these include uncontrolled hypertension or hypotension, renal abscesses, 
pyelonephritis, hydronephrosis, marked obesity, severe anemia, previous technical failure, 
uremia, anatomic abnormalities of kidney such as large renal tumors, arterial aneurysm and 
cysts (Table 1) (Madaio, 1990). Correction of these medical conditions with antihypertensive 
medication, antibiotics or blood transfusions makes possible the biopsy to be carried out 
safely. 
4. Preparation 
First, the patient’s past medical history information should be reviewed before the biopsy. 
Personal and family history of bleeding diathesis, and allergy to substances used during the 
procedure such as povidone-iodine should be evaluated. Second, a thorough physical 
examination should be undertaken to look for skin infection as well as anatomic anomalies 
(e.g. obesity) that could interfere with the procedure. An assessment of blood pressure 
control is also essential. 
A pre-biopsy laboratory evaluation is also made routinely and includes complete 
biochemical profile, complete blood count and urinalysis. Baseline coagulation parameters, 
including platelet count, prothrombin time, partial thromboplastin time and fibrinogen, are 
usually documented before biopsy procedure. Bleeding time is also commonly analyzed 
prior to the biopsy, but its role to predict post-biopsy bleeding remains controversial; it will 
be discussed in detail later in this chapter. Stopping all the medications that could disrupt 
normal coagulation should normally prevent post-procedural bleeding. Antiplatelet agents 
and non-steroidal anti-inflammatory drugs have to be withdrawn prior to the procedure for 
at least seven days. Performing a renal biopsy in patients on anticoagulation therapy is 
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always a medical challenge. Decision to stop the anticoagulants before the biopsy should be 
based on the patient’s thromboembolism risks. If the decision is made to do the biopsy, an 
anticoagulation bridge with intravenous anticoagulation (e.g. heparin) is needed in most 
cases.  
A good preparation is an essential step to minimize the risk of bleeding complications as 
well as to intervene promptly in case of an adverse event. 
 
Indications Contraindications 
Isolated hematuria 
Mild to moderate proteinuria 
Nephrotic syndrome 
Nephritic syndrome 
Glomerulonephritis suspicion 
Renal manifestations of 
systemic diseases 
Acute renal failure 
Chronic renal failure 
Renal tumor in selected 
patients 
Relative 
Uncontrolled hypertension 
Hypotension 
Renal abscesses 
Pyelonephritis 
Hydronephrosis 
Marked obesity 
Severe anemia 
Uremia 
Large renal tumors or cysts 
Solitary kidney 
Previous technical failure 
Atrophic kidney(s) 
Absolute 
Bleeding diathesis 
Anatomic abnormalities 
Uncooperative behavior 
Pregnancy 
 
Table 1. Indications and contraindications of kidney biopsy 
5. Procedure 
As mentioned earlier, percutaneous renal biopsy under ultrasound guidance is now the gold 
standard method to obtain renal tissue for the diagnosis of renal diseases. It is generally 
considered superior to other techniques because of its numerous advantages: it allows 
continuous visualization of both kidney and needle, can be done regardless of the renal 
function, avoids exposure to radiation, permits procedure to be performed at bedside and 
avoids the administration of nephrotoxic contrast media (Korbet, 2002). Several other biopsy 
techniques exist, such as laparoscopic, computed tomography (CT)-guided and transjugular 
renal biopsy. Here, we will focus mainly on ultrasound-guided techniques. 
An adequate tissue sample (Figure 1) permitting an accurate diagnosis of a glomerular 
disease with light microscopy usually contains 8 to 10 glomeruli. It must include 
juxtamedullary glomeruli due to their preferential involvement in focal segmental 
glomerulosclerosis. In these focal lesions, at least 25 glomeruli may be required to have 
greater than 95% chance of finding evidence of  such renal injury (Fogo, 2003). 
In 1988, the American College of Physicians (ACP) stated the minimal requirements (Table 
2) that a nephrology fellow must acquire to perform percutaneous renal biopsy safely (ACP, 
1988). It is interesting to note that in a recent survey among 133 nephrology trainees, 75.3% 
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of them reported that they had little or no training, or some training but not enough to feel 
competent in doing renal biopsy independently (Berns, 2010). 
 
Skills 
Cognitive skills 
Knowledge of: 
Indications and contraindications 
When to use open renal biopsy 
Renal and surrounding anatomy 
Technique to use and position of the biopsy needle 
Examining and handling tissue for histologic 
processing 
Complications and how to detect and treat them 
Medications required for the procedure 
Role of the biopsy in determining treatment 
Alternatives to the procedure 
Ability to: 
Provide medical monitoring and intervention 
Communicate the risks, benefits, and results to the 
patient for purposes of informed consent 
Technical skills 
Ability to: 
Choose appropriate biopsy needle 
Use appropriate techniques to localize the kidney 
Appropriately place biopsy needle and obtain tissue 
Table 2. Skills related to percutaneous renal biopsy (from ACP, 1988) 
The patient should provide an informed consent before the procedure. No oral intake is 
usually permitted after midnight on the day of the procedure, except for a light meal if the 
procedure is planned late in the morning or early in the afternoon. A well-trained 
nephrologist or radiologist at the radiology department, or at bedside if needed, usually 
performs the procedure. An intravenous access is placed to insure adequate hydration. Vital 
signs have to be monitored throughout the procedure. 
Kidney biopsies are usually performed with the patient in prone position, after the skin is 
properly disinfected and draped. This position provides the most rational approach to a 
retroperitoneal organ. It also brings the kidney closer to the posterior abdominal wall. Local 
anesthesia is usually carried out with lidocaine. Tissue biopsies are acquired from the lower 
pole of the kidney, next to the renal capsule, with the left kidney usually preferred for 
ergonomic reasons. The operator must be aware that subcapsular cortical samples have 
overrepresentation of sclerosis related to hypertension, aging and non-specific scarring 
(Fogo, 2003). Samples are obtained when the patient is holding his breath. One or two 
needle passes are routinely performed. 
Another approach, commonly used to perform liver biopsy, is the transjugular renal biopsy. 
This technique is usually performed in academic centers by well-trained interventional 
physicians (nephrologists or radiologists) and should be reserved for high-risk patients with 
contraindications to percutaneous renal biopsy such as liver disease, bleeding diathesis and 
obesity. The main disadvantage of this technique is lower diagnostic yield, mainly because 
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medulla needs to be traversed first before reaching the renal cortex. A recent retrospective 
study showed a good safety and efficacy of transjugular renal biopsy in 23 high-risk patients 
(Sarabu et al., 2010). An adequate tissue for histopathological diagnosis was obtained in 87% 
of patients. Three patients (13%) experienced bleeding requiring blood transfusion. Neither 
deaths nor embolization/nephrectomy were reported. 
A supine antero-lateral position (SALP) for percutaneous biopsy has been suggested 
recently (Gesualdo et al., 2008). It can be an interesting and useful alternative to the prone 
position for obese patients. This technique is also less invasive than a transjugular biopsy, 
and certainly provides a better diagnostic yield due to a direct access to the distal  
cortex. High-risk patients with a BMI >30 and/or respiratory difficulty underwent a SALP 
biopsy and were compared with low-risk (BMI ≤30 and/or no respiratory difficulty) 
patients receiving ultrasound-guided renal biopsy in either the prone position or SALP, 
for a total of 110 patients. There were a significantly better comfort compliance and less 
breathing difficulties for SALP patients. Post-procedure bleeding complications were 
minor in all three groups. The authors concluded that SALP may therefore be considered 
seriously for patients who otherwise would have been submitted to more invasive 
procedure. 
5.1 Optimal depth 
Pasquariello and colleagues (Pasquariello et al., 2007) published a novel approach to 
calculate the optimal depth needed to decrease significantly hemorrhagic complications, as 
well as tissue sample inadequacy. All 126 percutaneous native kidney biopsies, using a 14-
gauge automated biopsy gun under sonographic guidance, were performed with optimal 
depth previously calculated. Adequacy rate of specimens for diagnosis and complication 
rate were compared with retrospective data obtained for 123 biopsies. Incidence of bleeding 
complications was significantly reduced using the theoretical calculation of optimal depth, 
together with an adequate sampling permitting an accurate diagnostic evaluation from renal 
tissue. Depth where pushing the trigger was calculated by a mathematical formula defined 
below (1).  
 Optimal depth = BW/H-0.5 (1) 
BW represents the body weight expressed in hectograms and H the height expressed in 
centimeters. 
5.2 Real-time versus blind ultrasound 
Biopsy procedure can be performed under real-time or blind ultrasound-guided technique. 
Real-time method implies continuous visualization of the kidney for exact localization of the 
biopsy site (Figure 2). Blind method requires a sonographic localization of the kidney only 
before needle insertion. A proper needle placement is thereafter assessed by appropriate 
tissue resistance and observation of the respiratory excursion of the needle. A study by 
Maya and colleagues (Maya et al., 2007) showed that real-time ultrasound-guided technique 
provided a superior yield of kidney tissue and resulted in fewer bleeding complications. 
This retrospective study of 129 patients showed a higher mean number of glomeruli per 
biopsy in the sonographic-guided group compared to the blind biopsy group (18 ± 9 versus 
11 ± 9), and fewer large hematomas requiring intervention (0% versus 11%). 
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Fig. 1. Adequate tissue sampling 
5.3 Outpatient observation versus hospitalization 
The low occurrence rate of bleeding complications with percutaneous kidney biopsies 
performed under real-time ultrasound led to elective procedures in an outpatient setting 
using standardized protocols. Overnight hospitalization would not be therefore needed, 
reducing the overall cost of elective renal biopsies.  
 
 
Fig. 2. Real-time ultrasound biopsy in prone position 
A recent study by Maya and Allon (Maya & Allon, 2009) confirmed the safety and 
effectiveness of such an approach. During a 20-month period, 100 patients underwent a 
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percutaneous renal biopsy under real-time ultrasound guidance with a 16-gauge spring-
loaded biopsy gun. A majority of patients (91%) required only one or two needle passes, 
reflecting the technical advantage of the real-time ultrasound guidance. A color Doppler 
ultrasound was performed immediately after the procedure to exclude active bleeding. In 
this series, no patient experienced serious complications related to the biopsy. Only four 
patients were hospitalized because of an >4% decrease in their hematocrit. Neither blood 
transfusion nor selective embolization was needed for these patients. Nonetheless, one can 
argue that such an approach should be reserved for highly selected patients who do not 
need urgent renal biopsy in the setting of acute kidney injury or bleeding disorders.  
Common sense should therefore prevail regarding the decision to hospitalize or not a 
patient after biopsy. It is mainly an institution-based decision. At our hospital, we prefer to 
hospitalize all patients overnight after the biopsy. 
6. Needle 
Several types of needles have been used during medical history to perform percutaneous 
renal biopsy. In 1951, Iversen and Brun (Iversen & Brun, 1951) described a percutaneous 
native kidney biopsy technique using an aspiration needle. Later, Kark and Muehrcke (Kark 
& Muehrcke, 1954) published a technique whereby cutting needles were employed, such as 
the Franklin-Vim-Silverman and the Tru-Cut (Baxter, Deerfield, IL) needles. The automated 
biopsy-gun (Figure 3) became popular in the nineties based on its potential benefits in 
reducing bleeding complications, for shorter actual time the needle resides in the kidney, 
and the fact that it requires less dexterity by the operator (Madaio, 1990). A randomized 
prospective trial comparing the two methods showed adequate tissue sampling, but the 
extent of bleeding was more severe in the free-hand biopsy group (D. Kim et al., 1998). 
 
 
Fig. 3. Automated biopsy-gun 
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A number of different needle sizes are available for percutaneous biopsy techniques, 
ranging from 14 to 18 gauge (G). Needle gauge has a huge impact on the sample obtained. 
Eighteen- or 19-G needles are often unable to give a good specimen, and provide inadequate 
representation of vessels. In past years, there were concerns in the literature regarding 
bleeding risk with the use of larger needles. However, recent data (Tung et al., 1992; Song & 
Cronan, 1998; Nicholson et al., 2000; Manno et al., 2004) refuted such beliefs by showing that 
larger gauge needles provided better adequacy in tissue sampling and were not associated 
with higher complication rates. More specifically, a study (Nicholson et al., 2000) comparing 
14, 16, and 18-G needles in renal transplants demonstrated an improved diagnostic value 
with increased needle size and no significant difference in macroscopic hematuria between 
the three groups. Nevertheless, the use of 14-G needle may create more pain. Overall, 
utilization of 16 G needle appears to be the best compromise between patient comfort and 
histopathological diagnostic yield. 
7. Complications 
Complications associated with percutaneous renal biopsy can be categorized as minor (gross 
hematuria and silent hematoma), major (hematoma requiring transfusion and/or 
embolization) or catastrophic (loss of functional mass and death) (Mendelssohn & Cole, 
1995). Percutaneous renal biopsies using aspiration technique were associated with severe 
complications, mainly hemorrhage, with mortality rates of nearly 0.07% in large series 
reported in the fifties (Schwarz et al., 2005).  
 
Complications Rate of occurrence 
Minor 
Gross hematuria 
Silent hematoma 
 
0 to 6% (Maya et al. 2009) 
33.3% (Manno et al. 2004) 
Major 
Hematoma requiring transfusion 
and/or embolization 
 
1.2 % (Manno et al. 2004) 
Catastrophic 
Loss of functional mass 
Death 
 
6 per 10 000 (Schow et al. 1992) 
7 per 10 000 (Schow et al. 1992) 
Close to zero (Mendelssohn et al. 
1995)  
 
Table 3. Complications of percutaneous renal biopsy 
Two main technical advances have resulted in safer procedures: the ultrasound guidance 
and the automated core biopsy system (automated biopsy-gun). Rates of serious 
complications were as low as <1% in recent series, with an overall risk of kidney function 
loss of 6 per 10 000 and a mortality risk of 7 per 10 000 (Schow et al., 1992). Nonetheless, 
complications more commonly reported are transient gross hematuria and hematoma with a 
frequency ranging between 0% to 6% (Maya & Allon, 2009). A literature review published in 
1995 supports the opinion that the risk of catastrophic complications using the actual biopsy 
methods is close to zero (Mendelssohn & Cole, 1995). These differences observed in 
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complication rates may result from patient selection, biopsy technique, needle gauge, 
operator experience and number of needle passes. 
Despite the fact that percutaneous biopsy can be now considered as a procedure with almost 
no catastrophic complications if it is performed with standard techniques, it is always 
associated with minor complications that the attending physician must be aware of. There is 
obviously a transient damage to the collecting system and to the structures surrounding the 
kidney. This generates bleeding, creating symptoms such as hematuria and a drop in 
hemoglobin level (see below). Microscopic hematuria is normally seen in all patients who 
undergo a kidney biopsy (Altebarmakian et al., 1981), but is generally clinically insignificant 
and revolves spontaneously within 24 to 48 hours. On the other hand, macroscopic hematuria 
is seen less frequently, complicating up to 5 to 10% of patients (Marwah & Korbet, 1996). It is 
also generally clinically insignificant and self resolving in 48 hours. It can be severe, resulting 
in a significant loss of blood. It should also raise concerns for a concomitant hematoma or 
arteriovenous fistula, requiring further investigation and monitoring.  
Normally, a fall in hemoglobin level is observed after a percutaneous renal biopsy, with  
a decrease ≥1 g/dL reported in 20.8% of patients in a recent Japanese study (Ishikawa  
et al., 2009). A perinephric hematoma of more than 2 cm was associated with a 
significantly greater decrease in Hg level in this study. This drop is usually caused by 
several factors including local bleeding at the biopsy site (e.g. hematoma, hematuria), 
hemodilution secondary to hydration with intravenous fluids, recumbency and 
stimulation of anti-diuretic hormone secretion by pain; and it is not a good predictor of 
post-biopsy outcome. 
Subcapsular perinephric hematoma is certainly more common than previously noted in 
older retrospective studies where post-procedure sonography was not routinely performed. 
A recent series of patient showed that hematoma was seen in 33.3% of patients, with a mean 
surface area of 289.6 mm2 (Manno et al., 2004). These hematomas were clinically silent in 
90.4% of subjects, with 2.5% complaining of lumbar pain. It appears that there was no 
association between post-biopsy bleeding and the surface area of the hematoma. Another 
series reported hematomas in more than 86% of cases, and older studies using computerized 
tomography (CT) scanning also showed an incidence of 90%, depending on the timing of the 
evaluation. Furthermore, the clinician must be aware of an extremely rare complication that 
may be associated with a perinephric hematoma: the laceration of a lumbar artery passing 
over the lower pole of the kidney (K.T. Kim et al., 1991). 
Arteriovenous fistulas are also clinically silent complications of percutaneous renal biopsy. 
Angiography-based imaging studies reported an incidence of about 10%. The majority (over 
90%) resolved spontaneously a year later, requiring no invasive procedure. They rarely 
become a symptomatic aneurysm that causes high output cardiac failure, hypertension, 
hematuria and renal failure (by arterial steal). Due to the gravity of the potential 
complications related to arteriovenous fistulas, they should be monitored with Doppler 
ultrasound every 3 to 6 months (Korbet et al., 2002). 
In summary, there are numerous complications related to percutaneous kidney biopsy 
ranging from silent hematomas to uncontrolled bleeding with hemorrhagic shock. Clinicians 
must therefore be aware of these adverse events and investigate rapidly patients who 
present signs of clinical deterioration. This argues for an overnight observation of the 
patient after the procedure, with adequate monitoring of his vital signs, degree of hematuria 
and abdominal pain. 
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7.1 Predictors of bleeding complications 
Determining the predictors of bleeding complications related to percutaneous kidney biopsy 
has always been a matter of debate in the literature over the last decades, despite the fact 
that this procedure is routinely and frequently performed worldwide. There are scant 
prospective data regarding which baseline conditions (e.g. bleeding time, age) can affect 
significantly the outcomes. A recent Italian prospective study tried to answer this important 
question (Manno et al., 2004). The authors analyzed baseline characteristics and outcomes of 
471 consecutive native kidney percutaneous ultrasound-guided biopsies. Univariate and 
multivariate analysis of predictors of post-biopsy bleeding complications demonstrated a 
strong association between post-procedure bleeding and female gender, higher baseline 
partial thromboplastin time and age, as bleeding tends to occur less in older patients. 
Surprisingly, no association was made between bleeding time and post-biopsy bleeding. 
Patients with complications had exactly the same bleeding time than patients without any 
complications, but all patients with abnormal bleeding time received 8-D-arginine 
vasopressin (DDAVP), showing afterwards a normalization of their bleeding time prior to 
biopsy. Only 11 patients had increased bleeding time prior to biopsy, two with moderate 
von Willebrand factor deficiency and nine with moderate renal failure. Moreover, there was 
also no impact of the histologic diagnosis on the occurrence of post-biopsy bleeding. 
 
Predictors of post-biopsy bleeding 
Factors not associated with post-
biopsy bleeding 
Manno et al. 2004 
Younger age 
Female gender 
Elevated partial thromboplastin time
Ishikawa et al. 2009 
Perirenal hematoma ≥2.0 cm 
assessed immediately after biopsy 
PT-INR ≥1 
Mean blood pressure ≥105 mmHg 
Steroid use 
 
Manno et al. 2004 
Blood pressure 
Body weight 
Serum creatinine 
Proteinuria 
Needle gauge 
Waldo et al. 2009 
Absence of hematoma 1 h post-
biopsy 
Ishikawa et al. 2009 
Age 
Creatinine ≥2.0 mg/dL 
Table 4. Predictors of post-biopsy bleeding 
A recent retrospective study of 317 patients tried to find predictors of overt bleeding after 
renal biopsy (Ishikawa et al., 2009). More than 86% of patient presented a perirenal 
hematoma after biopsy, a majority with a diameter of less than 2 cm. A hematoma ≥2 cm 
was associated with a greater decrease in hemoglobin levels. The authors determined by 
multivariate analysis the clinical predictors of bleeding (Hb decrease ≥1.0 g/dL). Perirenal 
hematoma, prothrombin time-international normalized ratio (PT-INR), mean blood pressure 
and steroid use were found to be related to overt bleeding (Table 4). Of these factors, 
perirenal hematoma ≥2cm immediately after the biopsy was the strongest predictor, with a 
risk of severe anemia increased to about eight times. Post-biopsy ultrasound may therefore 
be a useful tool to discriminate patients with the highest risk of bleeding complications. 
However, a recent investigation studying the presence of a hematoma 1 hour post-biopsy as 
a predictor of major complications was not conclusive (Waldo et al., 2009). The absence of 
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hematoma was predictive of an uncomplicated post-biopsy evolution, with a negative 
predictive value of 95%. 
7.2 Role of bleeding time in predicting bleeding complications 
Utilization of bleeding time prior to the renal biopsy procedure remains controversial. 
Bleeding time is used frequently by nephrologists before biopsy, mainly for historical 
reasons, as a predictor of bleeding in spite of no clear evidence supporting its role. 
On the one hand, a widespread consensus among hematologists supports the fact that it is 
not a useful predictor of the risk of hemorrhage after a surgical procedure, especially if there 
is absence of a clinical history of bleeding disorder. Bleeding time could indeed be altered in 
several conditions including technique variability related to the operator, drugs (e.g. beta-
blockers, antibiotics) and various clinical states such as liver disorders and diabetes mellitus 
(Mattix & Singh, 1999). No study linking the bleeding risk of performing kidney biopsies 
with abnormal bleeding time has been published. Furthermore, an article describing the 
position of the College of American Pathologists and the American Society of Clinical 
Pathologists concluded that bleeding time can be a test useful for testing the response to 
DDAVP in uremic patients, but it is not a predictor of the bleeding risk in these patients 
(Peterson et al., 1998).  
On the other hand, recent data has shown that prolongation of the bleeding time is not 
without risk. It was found that the risk of post-biopsy hematoma increased by 21 % for each 
minute of bleeding time prolongation, conferring a two times greater risk of bleeding in 
patients in which such a rise was seen (Stratta et al., 2007). More recent data demonstrated 
the same increased risk of major bleeding complications in patients with prolonged bleeding 
time (Waldo et al., 2009). Moreover, a prospective study of liver biopsies performed without 
correcting the bleeding time prior to the procedure showed five times higher bleeding 
complications (Boberg et al., 1999).  
DDAVP seems to enhance the release of von Willebrand factor from endothelial cells into 
plasma. It also increases release of factor VII and adenosine triphosphate by platelets, as 
well as the uptake of serotonin. Studies have shown a normalization of the bleeding time by 
DDAVP infusion. Administration of this drug systematically regardless of bleeding time 
values appears to be cost-ineffective, considering that approximately 80% of patients had 
normal bleeding times, and it could be related to serious side effects such as hypertension 
and hyponatremia (Mattix & Singh, 1999; Korbet, 2002). However, a recent randomized 
controlled trial showed a significant advantage of a systematic DDAVP administration in 
patients without a significant renal impairment (Manno et al., 2011). 
8. Role of percutaneous biopsy in renal tumors 
Percutaneous renal biopsies also have a smaller role in the management of renal tumors in 
adults. Indeed, surgical resection permits a clear pathological diagnosis, as well as generally 
curing the patient from his/her malignancy. This is based on the fact that carcinomas 
represent 90% of all renal solid masses in adults when tumor size is greater than 40 mm on 
imaging studies (Lebret et al., 2007). 
Nevertheless, partial or total nephrectomies can be spared for renal masses less than 40 mm 
in size. A study from a French group showed that renal biopsy prior to surgical resection of 
a renal mass should be reserved for patients in whom imaging was not able to make an 
accurate diagnosis (Lebret et al., 2007). It mainly consisted of equivocal lesions that lacked 
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one or more radiological criteria for malignant lesions, or were less than 40 mm. In this 
single institution series of 432 patients, 119 percutaneous biopsies were performed in 101 
patients. A diagnosis of benign lesions was made in 20% biopsies together with 9 malignant 
lesions not requiring surgery (lymphoma and metastasis) (Table 5). Thus, 30.4% of patients 
were not candidates for nephrectomy. 
Performing such technique in patients with renal cancer is not without risk. In fact, biopsy 
tract seeding has been reported in 0.01% of cases in a large series (Smith, 1991, as cited in 
Lebret et al., 2007). This can be prevented by using coaxial system. In the series described 
above, no cancer seeding was reported, making percutaneous biopsy a safe procedure in the 
hands of well-experienced interventional physicians. 
 
Histological findings % of lesions 
Malignant 
Renal cell carcinoma 
Transitional cell carcinoma 
Metastasis 
Lymphoma 
Benign 
Oncocytoma 
Angiomyolipoma 
Renal abscess/xanthogranulomatosus  
pyelonephritis 
Inconclusive 
Normal parenchyma 
Necrotic tissue 
Inflammatory tissue 
59 
48 
3 
7 
<1 
20 
13 
3 
4 
21 
10 
<1 
10
Table 5. Histological findings in renal masses (from Lebret et al. 2007) 
Despite the fact that surgical resection remains the standard approach for patients with 
renal tumors, percutaneous biopsy could also be an alternative for particular cases. Fine 
needle aspiration of a renal mass can also be reserved for patients who would not be able to 
tolerate surgery, mainly elderly patients, and those with comorbid conditions. 
9. Conclusion 
Ultrasound-guided percutaneous renal biopsy is a safe procedure with a central role in the 
diagnosis of parenchymal kidney diseases. Real-time ultrasonography and automated 
biopsy-gun are the major technical improvements permitting the procedure to be performed 
with safety and effectiveness. It is accomplished in a hospital setting by well-trained 
radiologist or nephrologist. With recent technical advances, bleeding complications are quite 
rare, allowing a shorter observation period (6 to 8 hours) after the procedure in highly 
selected elective patients. 
Areas of uncertainty however still exist. Predictors of bleeding complications are difficult to 
define clearly. Age, female gender and elevated prothrombin time seem to correlate with an 
increased risk of post-biopsy bleeding. Ultrasound undertaken immediately after the biopsy 
procedure can be helpful to determine if the patient is at a risk of bleeding and should be 
observed for longer period. The role of bleeding time remains controversial to predict overt 
bleeding mainly due to the fact that no prospective data are available to guide the clinical 
practice. 
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Randomized controlled trials would therefore be needed to evaluate certain important 
questions mainly related to post-procedure bleeding. As approximately 1 to 2 million 
bleeding time tests are performed annually, it would be interesting to clarify its usefulness 
as a predictor of post-biopsy bleeding. 
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